Metropolis Healthcare Limited has reported a strong operating performance in the December quarter of FY26, with consolidated revenue rising around 26% year-on-year, supported by sustained demand in preventive health check-ups and specialty diagnostics.
In a regulatory filing submitted to stock exchanges on January 5, 2026, the company said the growth was driven by continued momentum in its TruHealth preventive and wellness portfolio, along with a sharp increase in specialty testing volumes across both B2C and B2B channels .
The diagnostics chain noted that expansion of its core diagnostics test menu, focus on high-end specialty testing, and ongoing in-house innovation helped scale its specialty business across its pan-India network during the quarter.
Acquisitions and segment-wise performance
Metropolis said integration of recent acquisitions — including Core Diagnostics, Scientific Pathology (Agra), Dr. Ahuja’s Pathology & Imaging Center (Dehradun), and Ambika Pathology (Kolhapur) — is progressing well, with synergies contributing to improved operational efficiency and operating leverage. Margins at Core Diagnostics remained stable sequentially, while the other acquired entities continued to outperform the company’s average margin profile.
During Q3 FY26, the TruHealth Wellness segment recorded year-on-year growth of around 35%, while the Specialty testing segment grew approximately 33% on a consolidated basis. B2C revenues increased by about 18%, while B2B revenues rose nearly 37%, supported by higher wallet share among customers and a greater contribution from specialty testing.
Standalone performance
On a standalone basis, Metropolis Healthcare reported revenue growth of approximately 15% year-on-year, aided by higher patient footfalls, increased test volumes, and a favourable product mix. The TruHealth wellness segment grew by about 23%, while the Specialty segment expanded 16% year-on-year.
The company also said its EBITDA margins expanded year-on-year, despite the December quarter typically being a seasonally weaker period for the diagnostics industry. The margin improvement reflects the resilience of operations and benefits from operating leverage, the filing added.
Metropolis clarified that the update is a business performance summary, and detailed financial results for Q3 FY26 will be released after approval by the Board of Directors. The reported figures remain subject to audit review .
